Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Benign prostatic hyperplasia (BPH) is a common condition in aging men causing lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease progression. Of the different alpha-1 adrenergic receptors (ARs) in the prostate, alpha-1a receptors are known to be central to prostatic smooth-muscle contraction. Recent studies have shown that patients with BPH may also have a predominance of alpha-1d receptors.

      Related collections

      Author and article information

      Affiliations
      [1 ] John H. Stroger Hospital of Cook County, Chicago, Illinois, USA, 60607.
      Journal
      Cochrane Database Syst Rev
      The Cochrane database of systematic reviews
      Wiley-Blackwell
      1469-493X
      1361-6137
      Oct 07 2009
      : 4
      19821408 10.1002/14651858.CD007360.pub2

      Comments

      Comment on this article